

## **Supplementary Results**


### ***Antiangiogenic Platinum Through Glycan Targeting***

*Erica J. Peterson<sup>1</sup>, A. Gerard Daniel<sup>1</sup>, Samantha J. Katner<sup>1</sup>, Lisa Bohlmann<sup>2</sup>, Chih-Wei Chang<sup>2</sup>, Anna Bezos<sup>3</sup>, Christopher R. Parish<sup>3</sup>, Mark von Itzstein<sup>2</sup>, Susan J. Berners-Price<sup>2</sup> and Nicholas P. Farrell<sup>1,2\*</sup>*


*<sup>1</sup>Department of Chemistry; Virginia Commonwealth University, Richmond 23221, Virginia, USA*

*<sup>2</sup>Institute for Glycomics, Griffith University, Gold Coast Campus, Southport, Queensland 4222, Australia*


*<sup>3</sup>John Curtin School of Medical Research, The Australian National University, Canberra, Australia*




**Supplementary Figure 1.** Highlighted individual regions from the DFT calculations of the optimized structure of TriplatinNC with a heparin hexamer [IdoA(2S)-GlcNS(6S)]<sub>3</sub> from **Figure 2c**. Sulfate clustering of individual platinum coordination spheres is apparent in Regions 1,3 and 4 while a diamine linker (Pt-NH<sub>2</sub>(CH<sub>2</sub>)<sub>6</sub>NH<sub>2</sub>-Pt) – oligosaccharide (sugar) backbone contact is seen in Region 2.



**Supplementary Figure 2.**  $^1\text{H}$ NMR spectra of Triplatin+ FPX + heparanase in anomeric region and the  $\text{Pt-H}_2\text{NCH}_2$  protons of Triplatin in 2.5 – 3.00 ppm region. (a) Triplatin + FPX no enzyme. Note the non-covalent contribution with  $A_1$  notations etc. from **Fig. 3a**. The major chemical shift changes of the spectrum are identical to **Fig. 3b (i)**. (b) Spectrum after 1h in presence of heparanase. (c) Spectrum after 24h in presence of heparanase. Note the appearance of upfield peaks in 2.8ppm region indicating formation of covalent  $\text{FPX-Pt-NH}_2\text{CH}_2$  species through Pt-Cl displacement. Peaks labelled **x** initially grow with time (a  $\rightarrow$  b) but anomeric region becomes complicated over time possibly due to presence of multiple species with different environments for the proposed Pt-sulfate covalent binding.



**Supplementary Figure 3.** Sensitivity of human umbilical vein epithelial cells (HUVECs) to cisplatin, Triplatin, and TriplatinNC treatments determined by the MTT growth inhibition assay. HUVECs were seeded in a 96-well plate in 100  $\mu l$  of media and allowed 24 h to attach. Cells were drug treated for a period of 24 h. After drug removal, cells were incubated with 0.5 mg/mL MTT reagent (3,4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) in media for 3 h at 37 °C. After reagent was removed, 100  $\mu l$  of DMSO was added to each well. The plate was then incubated on a shaker at room temperature in the dark. The spectrophotometric reading was taken at 570 nm using a microplate reader. The average  $\pm$  s.d. of two independent repeats is shown.



**Supplementary Figure 4.** Effects of cisplatin and TriplatinNC on serum-induced wound closure in HCT116 cells.  $5 \times 10^5$  HCT116s were seeded in a 24-well plate containing 1 ml media (RPMI containing 10% FBS). After cells reached confluence, a scratch was made on the monolayer using p10 pipette tips. The wells were washed 2x with PBS. The media was replaced with or without  $2\mu\text{M}$  cisplatin or TriplatinNC. The extent of closure of the scratch at 12 and 36 h was compared to the control by light microscopy, digital imaging, and analysis by ImageJ software. The results are reported as the average of two independent experiments.